Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts KRYS Hot Sheet
Join SI Premium – FREE
Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $1.70, $0.12 better than the analyst estimate of $1.58. Revenue for the quarter came in at $107.1 million versus the consensus estimate of $106.16 million.
For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can JetBlue still avoid bankruptcy? Analysis says yes, but it won’t be easy
- RBC Capital Downgrades Surgery Partners (SGRY) to Sector Perform
- Deen Cadi CPA Expands Independent Audit & Assurance Practice to Help Growing Businesses Establish Financial Credibility and Compete Nationwide
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
